About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 816 record(s)
Req # A-2023-000457
Adverse Drug Reactions (ADRs). Report numbers: E2B_00411389, E2B_04920318, E2B_05844531, E2B_05853179, E2B_05118337, E2B_05151349, E2B_05195930.Organization: Health Canada
November 2023
Req # A-2023-000559
Adverse Drug Reactions (ADRs) for ZOSTAVAX II. Report numbers: E2B_01071267, E2B_00614561, E2B_01171723, E2B_01575844, E2B_01578726, E2B_01843722, E2B_02095927, E2B_02126006, E2B_02130335, E2B_01440660.Organization: Health Canada
November 2023
Req # A-2023-000628
Adverse Drug Reactions (ADRs) for ENTYVIO. Report numbers: 001047411, E2B_06341293, E2B_06372245, E2B_06383431, E2B_06386949, E2B_06389814. ADRs for ONDANSETRON. Report numbers: E2B_06364582, E2B_06398719, E2B_06384325, E2B_06388111.Organization: Health Canada
November 2023
Req # A-2023-000631
Adverse Drug Reactions (ADRs) for MEZAVANT. Report numbers: 001042210, E2B_06389094. ADRs for MESALAZINE. Report numbers: E2B_06363129, E2B_06343271, E2B_06349976. ADR for ANTIHEMOPHILIC FACTOR. Report number: E2B_06361268. ADRs for C1 ESTERASE INHIBITOR (HUMAN). Report numbers: E2B_06405702, E2B_06381733, E2B_06362541, E2B_06333449.Organization: Health Canada
November 2023
Req # A-2023-000632
Adverse Drug Reaction (ADR) for CUVITRU. Report number: 001039475. ADRs for GAMMAGARD LIQUID. Report numbers: 001040660, 001039696, 001040672, 001039691, 001039699, 001040665. ADRs for IMMUNOGLOBULIN (HUMAN). Report numbers: E2B_06352393, E2B_06351696, E2B_06354052.Organization: Health Canada
November 2023
Req # A-2023-000640
Adverse Drug Reactions (ADRs). Report numbers: 001037727, 001042563, E2B_06389094, E2B_06347544, E2B_06362584.Organization: Health Canada
November 2023
Req # A-2023-000658
Adverse Drug Reactions (ADRs). Report numbers: E2B_04619567, E2B_04582728, E2B_03722288, E2B_04110358, E2B_02891039, E2B_02541469, E2B_05378319, E2B_01294965, E2B_03863914, E2B_06191407.Organization: Health Canada
November 2023
Req # A-2023-000670
Adverse Drug Reactions (ADRs). Report numbers: E2B_06381530, E2B_06401817, E2B_03046349, 001039522, 001039514, E2B_06400028, E2B_06262041, E2B_06178431, 001020862, E2B_06388027.Organization: Health Canada
November 2023
Req # A-2023-000671
Adverse Drug Reactions (ADRs). Report numbers: E2B_02239177, E2B_02869593.Organization: Health Canada
November 2023
Req # A-2023-000693
Adverse Drug Reactions (ADRs) for PATIROMER. Report numbers: E2B_06435279, E2B_06441728. ADRs for TAVNEOS. Report numbers: E2B_06450187, E2B_06459323. ADRs for REXULTI. Report numbers: 001046754, E2B_06452812. ADRs for REXULTI AND ARIPIPRAZOLE. Report numbers: E2B_06442226, E2B_06442785.Organization: Health Canada
November 2023